These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 1466961)

  • 1. Type-specific and cross-reactive neutralizing antisera against HIV elicited by V3-peptide heptalysine octomers.
    Looney DJ; Li M; Walfield A; Hosein B; Badel P; Wang CY; Wong-Staal F
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1381. PubMed ID: 1466961
    [No Abstract]   [Full Text] [Related]  

  • 2. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
    Davis D; Stephens DM; Carne CA; Lachmann PJ
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
    Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
    Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates.
    Haynes BF; Ma B; Montefiori DC; Wrin T; Petropoulos CJ; Sutherland LL; Scearce RM; Denton C; Xia SM; Korber BT; Liao HX
    Virology; 2006 Feb; 345(1):44-55. PubMed ID: 16242749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
    Vogel T; Kurth R; Norley S
    J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitopes of HIV-1 glycoproteins recognized by the human immune system.
    Laal S; Zolla-Pazner S
    Chem Immunol; 1993; 56():91-111. PubMed ID: 7680869
    [No Abstract]   [Full Text] [Related]  

  • 9. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
    Zolla-Pazner S; Zhong P; Revesz K; Volsky B; Williams C; Nyambi P; Gorny MK
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1254-8. PubMed ID: 15588347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shared antigenic epitopes on the V3 loop of HIV-1 gp120 and proteins on activated human T cells.
    Trujillo JR; Rogers RA; Brain JD
    Virology; 1998 Jun; 246(1):53-62. PubMed ID: 9656993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate.
    Chen CH; Jin L; Zhu C; Holz-Smith S; Matthews TJ
    J Virol; 2001 Jul; 75(14):6700-4. PubMed ID: 11413338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.
    Buchbinder A; Zolla-Pazner S; Karwowska S; Gorny MK; Burda ST
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1395. PubMed ID: 1466965
    [No Abstract]   [Full Text] [Related]  

  • 13. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope.
    Wu L; Yang ZY; Xu L; Welcher B; Winfrey S; Shao Y; Mascola JR; Nabel GJ
    Vaccine; 2006 Jun; 24(23):4995-5002. PubMed ID: 16690178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1.
    Zhang A; Geisler SC; Smith AD; Resnick DA; Li ML; Wang CY; Looney DJ; Wong-Staal F; Arnold E; Arnold GF
    Biol Chem; 1999 Mar; 380(3):365-74. PubMed ID: 10223339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary results of V3 loop peptide-primary neutralizing domain conjugate phase 1 vaccine trail.
    Rubinstein A; Goldstein H; Pettoello-Mantovani M; Cryz SJ
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S149-53. PubMed ID: 7865291
    [No Abstract]   [Full Text] [Related]  

  • 19. HIV-1-specific polyclonal and monoclonal antibodies raised with synthetic peptides: characterization and applications.
    Laman JD; Schellekens MM; Paddenburg D; Tersmette M; Langedijk JP; Boersma WJ; Claassen E
    Year Immunol; 1993; 7():63-8. PubMed ID: 7690509
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.